-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Beta-thalassemia is a hereditary anemia caused by lack or insufficiency of the beta chain of hemoglobin
Recently, a research article was published in the top medical journal Nature Medicine.
In this phase I clinical trial (NCT01639690), these patients received reduced intensity treatment (RIC) globin TNS9.
There were no accidental safety issues during the handling and infusion of cell products
stem cell
It can be seen that these relevant results emphasize the need to closely monitor β-thalassemia patients receiving treatment with globin carriers
These related results emphasize the need to closely monitor β-thalassemia patients receiving treatment with globin carriers
Original source:
Farid Boulad,et al.
Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial
in this message